BCAB
BCAB
NASDAQ · Biotechnology

Bioatla Inc

$1.83
-0.26 (-12.44%)
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +413.7% upside
Low Target $5.45
Average Target $9.40
High Target $11.97
Current Price $1.83
Current
$1.83
Target
$9.40
$5.45 $9.40 avg $11.97
Scenario Analysis
Bear Case
$5.45
197.8%
Low target
Base Case
$9.40
+413.7%
Avg target
Bull Case
$11.97
+554.1%
High target
Risk/Reward
2.8x
Favorable
Price in Context
52-Week High
$71.50
-97.4% from high
52-Week Low
$1.07
+71.0% from low
Target vs 52W High
$9.40
-86.9% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 38 82% $257.58 -12.5%
AMGN
Amgen Inc
Hold 42 43% $190.87 -59.0%
GILD
Gilead Sciences Inc
Strong Buy 36 83% $362.68 +115.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 82% $438.34 -19.2%
MRNA
Moderna Inc
Hold 31 32% $149.45 -35.4%
REGN
Regeneron Pharmaceuticals
Buy 36 72% $76.80 -91.9%
NTRA
Natera Inc
Strong Buy 31 90% $142.91 -55.7%
RVMD
Revolution Medicines Inc
Strong Buy 31 94% $114.11 -35.3%